부산대학교 도서관

Simple Summary: The monitoring of disease in patients with neuroendocrine tumors is challenging and requires specialized imaging techniques. To address these quests, somatostatin receptor-targeting molecular imaging modalities that can accurately visualize disease manifestations of neuroendocrine tumors have been proposed. However, the prognostic value of the total tumor volume, expression level, and related metrics has yet to be thouroughly understood. Historically, molecular imaging of somatostatin receptor (SSTR) expression in patients with neuroendocrine tumors (NET) was performed using SSTR scintigraphy (SRS). Sustained advances in medical imaging have led to its gradual replacement with SSTR positron-emission tomography (SSTR-PET). The higher sensitivity in comparison to SRS on the one hand and conventional cross-sectional imaging, on the other hand, enables more accurate staging and allows for image quantification. In addition, in recent years, a growing body of evidence has assessed the prognostic implications of SSTR-PET-derived prognostic biomarkers for NET patients, with the aim of risk stratification, outcome prognostication, and prediction of response to peptide receptor radionuclide therapy. In this narrative review, we give an overview of studies examining the prognostic value of advanced SSTR-PET-derived (semi-)quantitative metrics like tumor volume, uptake, and composite metrics. Complementing this analysis, a discussion of the current trends, clinical implications, and future directions is provided. [ABSTRACT FROM AUTHOR]